Method of treating muscle spasticity in patients with vertebral and spinal cord injury

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to neurology, and can be used in treatment of muscle spasticity in patients with spinal cord injury. For this purpose botulotoxin is introduced into iliolumbar muscle under control of X-ray computer tomography. Introduction of preparation is performed by dorsal access into proximal part of iliolumbar muscle at the level of LII-LIII vertebrae, 2-3 cm more laterally than spinous process. Depth of introduction is 8-10 cm.

EFFECT: method makes it possible to ensure efficient relief of local spasticity of iliolumbar muscle with absence of botulotoxin effect on other groups of muscles due to accurate introduction of preparation into definite region of said muscle.

2 ex

 

The present invention relates to medicine, in particular to methods for treating spasticity due to injuries and diseases of the Central nervous system.

As a prototype of the selected method of treatment of patients with spine-spinal cord injury, which consists in the introduction of botulinum toxin in the distal portion of the iliopsoas muscle on 3-4 cm lies lateral to the femoral artery and 1-2 cm distal to the inguinal ligament to a depth of 2-4 cm (see Wolfgang Jost / Pictorial Atlas of Botulinum Toxin Injection, UK, Quintessence books, 2008, s).

However, the introduction of the drug in the distal part of the muscle unsafe due to the proximity of the neurovascular bundle. In addition, spastic condition of the iliopsoas muscles causes flexion and rotation of the trunk, organisovalsa the ability to maintain a vertical posture and movement, so the introduction of the drug in the distal part of the muscle is not possible to achieve the correction of the deformation of body due to the small amount of muscle mass in the projection of the point of injection of botulinum toxin.

The task of the invention is a security administration of the drug and increase the efficiency of the procedure.

The problem is solved due to the fact that the introduction of botulinum toxin perform dorsally access to the proximal portion of the iliopsoas muscle at the level of LII-LIII vertebra, 2-3 cm lateral regions of the its spinous process to a depth of 8-10 cm under the control of x-ray computed tomography.

Method for the treatment of spasticity in patients with spinal-spinal cord injury is as follows. Conduct x-ray computed tomography of the lumbar spine, determine the point of introduction of botulinum toxin in the iliopsoas muscle at the level of LII-LIII vertebra, 2-3 cm lies lateral to the spinous process to a depth of 8-10 cm At this point the proximal part of the iliopsoas muscles under CT control injected the drug.

Clinical example 1. Patient S., aged 20, arrived for treatment in the Department of rehabilitation NIETO 09.01.2008 GS diagnosis: spine-spinal cord injury: compression-comminuted fracture of the C6 vertebra with injury and spinal cord compression, late period, spastic tetraparesis, neurogenic bladder, heterotopic ossification left hip; the condition after surgery - anterior decompression of the spinal cord, spinal fusion with allograft and the implant from nickeled-titanium.

Complaints on admission to the violation of self-care, mobility, difficulty maintaining upright posture and movement due to painful contractions of the muscles of the back and lower extremities, pain in the left thigh.

Anamnesis. Injury received when diving in water 16.06.06. Operated 21.06.06: decompression corporectomy C6 vertebra and the adjacent disk, anterior interbody spend lodes allograft-implant from nickeled-titanium. In the postoperative period increased strength in the upper extremities appeared active movement in the legs, arbitrary urination and defecation. In 2006-2007 received courses of rehabilitation in rehabilitation clinics with positive regression of motor disorders, pelvic floor disorders, improve self-service.

Data of objective examination. C-shaped scoliotic deformity in the thoracolumbar division II stuurgroep voltage of the long back muscles in nijaguna and lumbar regions. Palpation of the spine painless. Pathological mobility no. The bends "back", "left" in the lumbar spine are not possible due to spastic muscle tension, "forward" and "right" is limited to 50% of normal. When you try to take a vertical position there is an overwhelming bending of the body with a left turn. Reflexes with triceps, biceps muscle of the shoulder and preclusively muscles in normal, d=s. Knee and ankle reflexes increased, d=s, clonus stop and patellas. The abdominal reflexes are absent, cremasteric and anal reflexes saved. Muscle tone in the upper limbs increased slightly (2 points for Asporto), muscle tone in the lower extremities increased significantly (up to 4 points) in the distal and roughly in the proximal. Significantly limited by the inner and outer whom I rotation, adduction and abduction of the left hip joint. Active movement in other joints of the upper and lower extremities in full. Motor score ASIA key muscles of the upper extremities - 46, lower extremities 42 points. Movement is possible in a wheelchair.

The self-assessment carried out by using Functional assessment scale for patients with spinal cord injury. Scores on the scale items were: moving bed 23, meal - 30, moving within rooms - 53, the movement is in a wheelchair 75, observance of personal hygiene - 34, dress - 34, the implementation of social skills - 41 points. Walking with the use of means of support is not possible.

Conducted introduction of botulinum toxin dorsally access to the proximal portion of the iliopsoas muscle on the left at the level of LII-LIII vertebra, 2-3 cm lies lateral to the spinous process to a depth of 8 cm Procedure carried out to reduce the muscle tone of the iliopsoas muscles and providing opportunities for independent walking. The introduction was carried out under the control of computer tomography.

The dynamics. The patient felt the effect seven days after injection of botulinum toxin, completely violent bending of the body when walking disappeared after 14 days and was not renewed within two years of observation.

Data of objective inspection: an upright position scoliosis is missing, movement in the lumbar spine in all directions amount to 50% of normal. The patient may be in a vertical position to one hour, to go based on the "canadian" hockey sticks to 400 meters without resting. Evaluation of self-service in the dynamics of demonstrated achievement of maximum possible performance on all points: move-in-bed - 25, meal - 30, moving within rooms - 60, movement - 75, observance of personal hygiene - 35, dressing - 40, the implementation of social skills - 45 points. Currently, the patient is moved based on a reed. Significantly improved quality of life - patient themselves completely to serve the mobile.

Clinical example 2. Patient P., 24 years old, was admitted for treatment at the Department of rehabilitation NIETO 13.09.2010, with a diagnosis of spine-spinal cord injury: compression fracture of the C5 vertebra with injury and spinal cord compression, late period, spastic tetraparesis, neurogenic bladder, the condition after surgery: anterior decompression of the spinal cord, spinal fusion with allograft and the cage.

Complaints on admission to the limitation of movements in the upper and lower extremities, impaired self-care, mobility, difficulty maintaining upright posture and inability to travel due to painful contractions of the muscles of the back the lower extremities.

Anamnesis. Injury received when diving in water 24.07.08. Operated 25.07.08: decompression of the spinal cord, anterior interbody fusion with allograft and cage. In the postoperative period increased strength in the upper extremities appeared active movement in the legs, arbitrary urination and defecation. In 2008-2009 received courses of rehabilitation treatment in a rehabilitation unit with positive regression of motor disorders, pelvic floor disorders, improve self-service. In 2008 with the aim of reducing the tone of the iliopsoas muscle was performed injection of botulinum toxin into the distal part of the muscle by well-known methods (WolfgangJost, 2008) - the dynamics of change in spasticity - minimal (the tone of the hip flexor was 4 points on Ashforth).

Data of objective examination. C-shaped scoliotic deformity in the thoracolumbar division III senior Pronounced stress of the long back muscles in nijaguna and lumbar regions. Palpation of the painful back muscles. Pathological mobility no. The bends "back", "left" in the lumbar spine are not possible due to spastic muscle tension, "forward" and "right" is limited to 75% of normal. When you try to take a vertical position there is an overwhelming bending of the body with a left turn. The position lying on his stomach takes hardly su is bedstvie involuntary flexion of the trunk and left hip. Reflexes with triceps, biceps muscle of the shoulder and preclusively muscles in normal, d=s. Knee and ankle reflexes increased, d=s, clonus stop and patellas. The abdominal reflexes are absent, cremasteric and anal reflexes saved. Muscle tone in the upper limbs increased slightly (2 points for Asporto), muscle tone in the lower extremities increased significantly (up to 4 points) in the distal and coarse (5 points) in the proximal. Significantly limited internal and external rotation, adduction and abduction in the hip joints, more to the left. Active movement in other joints of the upper and lower extremities in full. Motor score ASIA key muscles of the upper extremities - 40, lower extremities 36 points. Movement is possible in a wheelchair.

The self-assessment carried out by using Functional assessment scale for patients with spinal cord injury. Scores on the scale items were: moving bed 19, meal - 28, moving within rooms - 24, the movement is in a wheelchair 50, observance of personal hygiene - 28, dressing - 20, the implementation of social skills - 34 points. Walking with the use of means of support is not possible.

Injection of botulinum toxin was done dorsally access to the proximal portion of the iliopsoas muscle at the level of LII-LIII vertebra, 2-3 cm is aerolinee spinous process to a depth of 10 cm The procedure was carried out to reduce the muscle tone of the iliopsoas muscles and providing opportunities for independent walking. The introduction was carried out under the control of computer tomography.

The dynamics. The patient felt the effect eight days after injection of botulinum toxin: stoped back pain, completely violent bending of the body when making a vertical posture disappeared after 20 days and was not renewed within four months of observation.

Data of objective inspection: upright scoliosis 0/1 degree of motion in the lumbar spine in all directions amount to 50% of normal. The patient may be in a vertical position to one hour, to go based on the Walker up to 100 meters with the rest. Evaluation of self-service in the dynamics showed increased performance on all points:

move-in-bed - 22, meal - 30, moving within rooms - 40, the movement of the wheelchair - 60, observance of personal hygiene - 31, dressing - 30, the implementation of social skills - 39 points.

The proposed method for the treatment of spasticity in patients with spinal-spinal cord injury dorsally access under the control of x-ray computed tomography safe and effective. So, in the case when the spasticity of the muscles restricted riabilitazione the capabilities of the patient, the introduction of botulinum toxin could make the local spasticity iliopsoas muscle with no effect on other groups of muscles, and improve self-service and mobility of the patient.

The proposed method is simple and requires only a neurologist specializing in botulinum toxin therapy and x-ray computer tomograph.

Method for the treatment of spasticity in patients with spinal-spinal cord injury, which consists in the introduction of botulinum toxin in the iliopsoas muscle, characterized in that the drug carry out dorsally access to the proximal portion of the iliopsoas muscle at the level of LII-LIII vertebra, 2-3 cm lies lateral to the spinous process at a depth of 8-10 cm under the control of x-ray computed tomography.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to an amorphous form of N-{2- fluorine-5-[3-(thiophen-2-carbonyl)-pyrazolo[1,5-a]-pyrimidin-7-yl]-phenyl}-N-methyl-acetamide, methods for preparing it.

EFFECT: preparing the pharmaceutical compositions for GABA-receptor inhibition containing said form, and also to using them as a drug for treating and/or preventing anxiety, epilepsy, sleeping disorder and sleeplessness, for induction of sedative-hypnotic effect, for anaesthesia and muscular relaxation and for time modulation required for sleep induction and duration.

12 cl, 4 dwg

Gsk-3 inhibitors // 2449998

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns applying urea derivatives or their pharmaceutically acceptable salts characterised by formula , wherein RB is specified in: while R3, R4, R'2, R'3, R'4, R'5, and R'6 represent hydrogen as GSK-3 inhibitors, pharmaceutical compositions containing them, and using them for treating and/or preventing disorders the development of which involves GSK-3.

EFFECT: preparing the pharmaceutical compositions containing them, and using them for treating and/or preventing disorders the development of which involves GSK-3.

14 cl, 2 ex, 1 tbl, 4 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to novel compound, namely to N-(5-chlorfuran-2-ylcarbonyl)-3,7-diazabicyclo[3.3.0]octane or its pharmaceutically acceptable salts, pharmaceutical compositions for treatment of conditions and disorders associated with dysfunction of central nervous system, containing said compound, as well as methods of treatment. Claimed compound demonstrates selectivity with respect to neuron nicotine receptors of subtype α4β2 in central nervous system (CNS) and bind with them with high affinity.

EFFECT: compound and compositions based on it can be applied for treatment and/or prevention of wide spectrum of diseases and disorders, in particular, CNS disorders.

6 cl, 1 tbl, 11 ex

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of general formula where R1, R2 and R3 are independently selected from a group consisting of hydrogen, halogen and lower alkyl containing 1-6 carbon atoms; R4 denotes a residue given in the claim; R5 denotes hydrogen or methyl; R10 is selected from a group consisting of: (i) hydrogen; (ii) (C1-C10) alkyl; (iii) (C1-C10)alkyl, substituted with one or more substitutes independently selected from a group consisting of -N(CH3)2, morpholinyl, (C1-C4) alkoxy, hydroxyl, -CON(CH3)2 and halogen; (iv) monocyclic (C3-C8) cycloalkyl containing one N heteroatom; (v) 9-methyl-9-azabicyclo[3.3.1]nonane; (vi) phenyl; (vii) phenyl substituted with one or more (C1-C4)alkoxy; R11 is selected from a group consisting of hydrogen and (C1-C10)alkyl; or R10, R11 and a nitrogen atom with which they are bonded, together, form a nitric heterocycle or a substituted nitric heterocycle, such as given in the claim. The invention also relates to a pharmaceutical composition, having serotonin type 3 receptor modulating capacity and a method of treating a disorder which depends on serotonin type 3 receptor modulation.

EFFECT: compounds of formula II as serotonin type 3 receptor modulators.

18 cl, 1 tbl, 159 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel substituted methyl-amines of general formula 1, having serotonin 5-HT6 receptor antagonist properties. In formula 1 , W is naphthalene, indolysin or quinoline; R1 is hydrogen, fluorine, chlorine, methyl; R2 is hydrogen, fluorine, methyl, phenyl, thiophen-2-yl, furan-2-yl, pyridyl, piperazin-1-yl or 4-methylpiperazin-1-yl; R3 is methyl; or W is benzene, R3 assumes the value given above; R1 is 3-Cl, R2 is 3-piperazin-1-yl or 3-(4-methylpiperazin-1-yl); or R1 is hydrogen, R2 is phenyl or pyridyl; or R1 is hydrogen, fluorine, chlorine, methyl; R2 is 4-piperazin-1-yl or 4-(4-methylpiperazin-1-yl); or W is oxazole, R3 is optionally substituted methyl; R1 is chlorine or fluorine, R2 is methyl, or R1 is hydrogen, fluorine, chlorine, methyl; R2 is piperazin-1-yl, 4-methylpiperazin-1-yl, or R1 is chlorine, fluorine or methyl; R2 is furan-2-yl, or R1 is hydrogen, fluorine, chlorine, methyl; R2 is furan-2-yl, R3 is (tetrahydrofuran-2-yl)methyl, or R1 is hydrogen, fluorine, chlorine, methyl; R2 is thiophen-2-yl, R3 is 2-methoxyethyl, or R1 is chlorine or fluorine, R2 is thiophen-2-yl, R3 is methyl.

EFFECT: compounds can be used to treat central nervous system (CNS) diseases, such as psychiatric disorders, schizophrenia, anxiety disorders, as well as for improving mental capacity, for treating obesity or for studying the molecular mechanism of inhibiting serotonin 5-HT6 receptors.

15 cl, 27 dwg, 2 tbl, 25 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical agents and concerns an delayed-release oral tablet containing: (a) 10-80 wt % 1-{[(α-isobutanoyloxyehtoxy)carbonyl]aminomethyl)-1-cyclohexane acetic acid, and (b) 1-30 wt % of a fatty compound, such as glycerine ester, lauryl alcohol, myristyl alcohol, stearyl alcohol, cetyl alcohol, cytostearyl alcohol, palmitoyl alcohol, ouricury wax, hydrated vegetable oil, candelilla wax, esparto wax, stearic acid, hard wax, beeswax, glyco wax, hydrated castor oil and carnauba wax or their combination, where the value wt % is calculated by total dry weight of the dosage form which when taken by a human patient on an empty stomach per 1-{[(α-isobutanoyloxyehtoxy)carbonyl]aminomethyl)-1-cyclohexane acetic acid 1100-1300 mg provides the plasma gabapentin concentration profile Cmax 3-6 mcg/ml at Tmax 4-7 hours and AUC 30-70 mcgh/ml; when taken by a human patient after meal per 1-{[(α-isobutanoyloxyehtoxy)carbonyl]aminomethyl)-1-cyclohexane acetic acid 1100-1300 mg provides the plasma gabapentin concentration profile Cmax 5-8 mcg/ml at Tmax 6-11 h and AUC 60-110 mcgh/ml. What is also offered is application of 1-{[(α-isobutanoyloxyehtoxy)carbonyl]aminomethyl)-1-cyclohexane acetic acid for preparing a delayed-release tablet for treating restless leg syndrome and postherpetic neuralgia.

EFFECT: tablets under the invention provide improved pharmacokinetic profile of gabapentin.

17 cl, 8 dwg, 2 tbl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to 1H-quinazoline-2,4-diones of formula and to their pharmaceutically acceptable salts where R1 and R2 have the values specified in cl. 1 of the patent claim. The specified compounds exhibit antagonistic activity with respect to the AMPA receptor.

EFFECT: reception of a pharmaceutical composition for preparing a preparation used for treating a condition mediated by the AMPA receptor and first of all for treating epilepsy or schizophrenia.

8 cl, 81 ex

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of formula , where X denotes S; R1 and R2 taken together with atoms to which they are bonded form a 5-member carbocycle, substituted with up to two substitutes selected from alkyl and CF3; R3 is selected from a group consisting of a hydrogen atom and C1-8-alkyl; R3a denotes a hydrogen atom; R4 denotes a hydrogen atom; R4a denotes a hydrogen atom; R5 denotes a hydrogen atom; R5a denotes a hydrogen atom; R6 denotes a hydrogen atom; R6a denotes a hydrogen atom; R7 denotes a hydrogen atom; or pharmaceutically acceptable salts thereof. The invention also relates to compounds of the given formula, compounds selected from the group, as well as a pharmaceutical composition.

EFFECT: obtaining novel biologically active compounds which modulate serotonin receptor activity.

6 cl, 19 ex, 1 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of formula (I) given below or pharmaceutically acceptable salts thereof:

[where: each of X, Y, Z and W independently denotes a methane group which optionally contains substitutes selected from a group of substitutes α, or a nitrogen atom (except when all elements X, Y, Z and W denote a methane group which optionally contain substitutes selected from the group of substitutes α); A denotes -(C(R3)(R4))m1-; B denotes -O-; D denotes -C(O)-; m1 equals 0; Q denotes a methane group or a nitrogen atom; R denotes a group of formula (II)

, where R6 denotes a lower alkyl group; R7 and R8, together with the nitrogen atom with which they are bonded, form a 5-6-member nitrogen-containing aliphatic heterocyclic group; and where the group of substitutes α includes the following substitutes. Group of substitutes α: halogen atom, hydroxyl group, lower alkyl group, alkoxyl group (said group can be substituted with a cycloalkyl group), amino group, mono- or disubstituted lower alkylamino group, aryl group (said group can be substituted with a halogen atom, a -SO2CH3 group), aryloxy group (said group can be substituted with a halogen atom), heteroaryl group, where 'heteroaryl group' denotes a 5- or 6-member monocyclic saturated or unsaturated group containing 1-2 heteroatoms selected from an oxygen atom or a nitrogen atom (said group can be substituted with an alkoxyl group, alkyl group). The invention also relates to a histamine 3 receptor antagonist, histamine 3 receptor inverse agonist, a prophylactic or medicinal agent, as well as a pharmaceutical composition.

EFFECT: obtaining novel biologically active compounds having histamine H3 receptor antagonist or inverse agonist action.

15 cl, 57 ex, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: described are novel azole compounds, which contain carbamoyl group, of general formula IX: where A stands for azole group of general structural formula or G stands for ring, selected from group, consisting of piperonyl, indanyl, naphtyl, possibly substituted phenyl, benzodioxole and phenoxymethyl, (values of radicals are given in the invention formula), their pharmaceutically acceptable salts and pharmaceutical compositions, containing them, which can be applied for treatment of various central nervous system disorders, especially such as anxiety, depression, convulsions, epilepsy, migraine, bipolar disorder, medication abuse, smoking, ADHD, obesity, sleep disorder, neurogenic pain, stroke, cognitive impairment, neurodegeneration and muscle spasm.

EFFECT: obtaining novel azole compounds and their pharmaceutically acceptable salts and pharmaceutical compositions, containing them, which can be applied for treatment of various central nervous system disorders.

71 cl, 3 tbl, 199 ex

FIELD: food industry.

SUBSTANCE: Bifidobacterium bifidum 79-94 strain possessing acid-forming activity, antagonistic activity with regard to pathogenic and opportunistic microorganisms is deposited in the State Collection of Normal Microflora Microorganisms of Federal State Academic Institution "G. N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology" under the Federal Service for Consumer Rights Protection and Human Welfare (Rospotrebnadzor) under Registration Number 231 and may be used for production of cultured milk products, food products, hygienic and cosmetic aids, dietary supplements and bacterial preparations.

EFFECT: invention allows to produce cultured milk, fermented and non-fermented food products, hygienic and cosmetic aids, dietary supplements and bacterial preparations ensuring normalisation of microflora in the human organism.

2 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: Bifidobacterium adolescentis PBB-3 strain is isolated from the intestinal contents of a healthy adult person and is deposited in the National Collection of Normal Microflora of the G.N.Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology under registration number 218. The strain propagates in different culture media with accumulation of production biomass with high concentration of bifidobacteria.

EFFECT: strain has acid-forming activity, antagonistic activity on pathogenic and opportunistic microorganisms and ferments milk, which enables its use to obtain a bifido-containing product.

2 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: Bifidobacterium longum ABD-3 strain is isolated from the intestinal contents of a healthy adult person and is deposited in the National Collection of Normal Microflora of the G.N.Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology under registration number 212. The strain propagates in different culture media with accumulation of production biomass with high concentration of bifidobacteria.

EFFECT: strain has acid-forming activity, antagonistic activity on pathogenic and opportunistic microorganisms, which enables its use as a biologically active component to obtain a bifido-containing product.

2 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: Bifidobacterium longum ABD-7 strain is isolated from the intestinal contents of a healthy adult person and is deposited in the National Collection of Normal Microflora of the G.N.Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology under registration number 221. The strain propagates in different culture media with accumulation of production biomass with high concentration of bifidobacteria.

EFFECT: Bifidobacterium longum ABD-7 strain has acid-forming activity, antagonistic activity on pathogenic and opportunistic microorganisms and ferments milk, which enables its use to obtain a bifido-containing product.

2 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: Bifidobacterium adolescentis BK-14 strain is isolated from the intestinal contents of a healthy adult person and is deposited in the National Collection of Normal Microflora of the G.N.Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology under registration number 213. The strain propagates in different culture media with accumulation of production biomass with high concentration of bifidobacteria.

EFFECT: strain has acid-forming activity, antagonistic activity on pathogenic and opportunistic microorganisms and ferments milk, which enables its use to obtain a bifido-containing product.

2 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: Bifidobacterium adolescentis PBB-7 strain is isolated from the intestinal contents of a healthy adult person and is deposited in the National Collection of Normal Microflora of the G.N.Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology under registration number 214. The strain propagates in different culture media with accumulation of production biomass with high concentration of bifidobacteria.

EFFECT: strain has acid-forming activity, antagonistic activity on pathogenic and opportunistic microorganisms and ferments milk, which enables its use to obtain a bifido-containing product.

2 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: Bifidobacterium bifidum 73-1 strain is isolated from the intestinal contents of a healthy infant and is deposited in the National Collection of Normal Microflora of the G.N.Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology under registration number 216. The strain actively propagates in a culture medium with accumulation of production biomass with high concentration of bifidobacteria in 16-24 hours of culturing.

EFFECT: strain has acid-forming activity, antagonistic activity on pathogenic and opportunistic microorganisms and ferments milk, which enables its use to obtain a bifido-containing product.

2 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention relates to food, cosmetic, biotechnology and medical industry. The Bifidobacterium bifidum 74-22 strain has acid-forming activity and antagonistic activity on pathogenic and opportunistic microorganisms, and is deposited in the National Collection of Normal Microflora of the G.N.Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology under registration number 244.

EFFECT: invention enables to obtain fermented milk products, fermented and unfermented food products, sanitary and cosmetic agents, biologically active additives and bacterial preparations, which enable to normalise microbiocenosis of the human body, including gastrointestinal and urogenital tracts, skin and mucous covers.

2 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention relates to food, cosmetic, biotechnology and medical industry. The Bifidobacterium bifidum 74-21 strain, having acid-forming activity, antagonistic activity on pathogenic and opportunistic microorganisms, is deposited in the National Collection of Normal Microflora of the G.N.Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology under registration number 243 and can be used in producing fermented milk products, food products, sanitary and cosmetic agents, biologically active additives and bacterial preparations.

EFFECT: invention enables to obtain fermented milk products, fermented and unfermented food products, sanitary and cosmetic agents, biologically active additives and bacterial preparations, which enable to normalise microbiocenosis of the human body, including gastrointestinal and urogenital tracts, skin and mucous covers.

2 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention relates to food, cosmetic, biotechnology and medical industry. The Bifidobacterium bifidum 79-93 strain, having acid-forming activity, antagonistic activity on pathogenic and opportunistic microorganisms, is deposited in the National Collection of Normal Microflora of the G.N.Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology under registration number 246 and can be used in producing fermented milk products, food products, sanitary and cosmetic agents, biologically active additives and bacterial preparations.

EFFECT: invention enables to obtain fermented milk products, fermented and unfermented food products, sanitary and cosmetic agents, biologically active additives and bacterial preparations, which enable to normalise microbiocenosis of the human body, including gastrointestinal and urogenital tracts, skin and mucous covers.

2 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, in particular to cardiosurgery. Before operation patient's height and weight are determined. Area of their body surface and individual, normal for said patient volume of left auricle is calculated. Volume of left auricle is instrumentally determined, after reduction of the obtained value by 20%, its surface area before reduction is calculated. During operation on open heart section of reduction is selected and its area is calculated. Obtained value is subtracted from area of left auricle surface before reduction. By remainder volume of left auricle obtained after reduction is calculated. Obtained volume is compared with the desirable one and necessity of reduction of selected zone and continuance of reduction is estimated. In case of necessity reduction of selected zone is performed. New section of reduction is selected, its area is calculated and described above algorithm is repeated. In case if there is no necessity of reduction, procedure of atrioplasty is stopped.

EFFECT: method makes it possible to obtain controlled reduction of left auricle volume to normal, which results in increase of respiratory volume, reduction of time of artificial lung ventilation after operation, reduction of the number of complications associated with respiration.

3 dwg

Up!